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Abstract
We present provisional estimates of influenza vaccine effectiveness (VE) for the NZ 2013 season. 
A case test-negative study was used to estimate propensity adjusted vaccine effectiveness. 
Influenza vaccination provided 52% (95% confidence interval (CI): 27% to 68%) protection 
against laboratory-confirmed influenza hospitalisation and 53% (95% CI: 28% to 70%) against 
laboratory-confirmed influenza in patients presenting to general practice.
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Background
Influenza infection causes a significant burden of illness in adults and children [1, 2]. 
Seasonal trivalent influenza vaccines (TIV) are effective in preventing a range of laboratory 
confirmed outcomes [3], but effectiveness varies by severity and season, the presence of 
comorbidities and age [4, 5].
The SHIVERS study (Southern Hemisphere Influenza Vaccine Effectiveness, Research and 
Surveillance) has allowed estimation of vaccine effectiveness (VE) against hospitalised 
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influenza since 2012 and against influenza presenting to primary care (general practice) 
since 2013.
In New Zealand (NZ) seasonal unadjuvanted inactivated TIV is available annually free of 
charge to all adults aged 65 years and over, pregnant women and all those over 6 months of 
age with chronic medical conditions that are likely to increase severity of infection. The 
vaccines are also available on the private market for all others over 6 months of age. Two 
commercial vaccine products were available on the NZ market in 2013: Fluarix® 
(GlaxoSmithKline) and Fluvax® (bioCSL). Both vaccines contained A/California/7/2009 
(H1N1)-like virus, A/Victoria/36/2011 (H3N2)-like virus and B/Wisconsin/1/2010-like 
virus (belonging to B/Yamagata/16/88 lineage).
Using the case test-negative design we estimated the effectiveness of these two seasonal TIV 
products in preventing laboratory-confirmed influenza in patients hospitalised with severe 
acute respiratory infections (SARI) and in patients presenting to general practice with an 
influenza-like illness (ILI) during the 2013 season.
Methods
Ethics approval for the study was obtained from the Northern A Health and Disability Ethics 
Committee (NTX/11/11/102 AM02).
Study Design
In both hospital and community settings, we conducted a standard case test-negative design 
[6] drawing on an urban population of approximately 838,000 people in Central, South and 
East Auckland,.
For community cases we undertook purposeful recruitment of 18 general practices, covering 
103,884 enrolled patients representative of the population of the area. The practices 
recruited individuals aged 6 months and older who presented to a general practitioner or 
practice nurse with an ILI, defined as a history of fever or measured fever of ≥38°C and 
cough, with onset during the preceding 10 days [7].
For hospitalised patients we enrolled individuals aged 6 months and older who were 
admitted with SARI to one of the four public hospitals, Middlemore, Kidz First Children’s, 
Auckland City and Starship Children’s. Based on the World Health Organization definition, 
SARI was defined as hospitalisation with a patient-reported history of a fever or a measured 
temperature ≥38°C, cough, and onset within the past 10 days [8].
Recruitment was undertaken from 29 April to 29 September 2013.
A confirmed case of influenza was defined as a SARI or ILI patient with a positive 
laboratory result for any influenza virus detected by real time reverse transcription 
polymerase chain reaction (RT-PCR), while non-cases (controls) were patients with SARI or 
ILI who tested negative to all influenza viruses.
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All patients presenting to one of the sentinel general practices with suspected respiratory 
infections were screened by the general practitioner or nurse for ILI. All identified ILI cases 
were entered on an electronic form in the practice management system and a nasopharyngeal 
or throat swab was collected for influenza testing from all consenting patients.
SARI patients were identified following screening of admissions for respiratory disease by 
dedicated research nurses. Overnight admissions of patients with respiratory symptoms were 
screened the following day. All patients satisfying the SARI case definition were invited to 
participate. Patients who gave verbal consent completed a case report form and provided a 
nasopharyngeal swab or aspirate for influenza testing.
Excluded from the analysis were patients with incomplete data for vaccination status or age, 
children under 9 years who were only given one dose of TIV, patients who were vaccinated 
less than 14 days before admission, or patients who were swabbed more than 10 days after 
the onset of symptoms. For patients with multiple episodes the first influenza positive 
episode was used for analysis, or the first illness episode if there was no influenza positive 
episode.
Participant information
For all ILI cases, variables extracted from the electronic form and patient management 
system included age, sex, ethnicity, socioeconomic status as identified by the NZ 
deprivation status (a meshblock measure reflecting eight dimensions of deprivation 
distributed into deciles) [9], a subjective assessment of obesity by the clinician, chronic 
medical conditions and current smoking status.
Similar information was collected for all SARI patients but for this group we also collected a 
patient or caregiver reported measure of dependence (which assessed requirement for 
assistance with normal activity or full dependency on nursing care); a simple frailty measure 
based on use of long term oxygen; a history of chronic medical conditions; and a self-
defined, standardised functional well-being health status score from a national survey [10], 
combining fair or poor well-being versus all others.
SARI case vaccination status for the 12 months prior to hospitalisation was determined by 
self-report with reliability assessed against electronic administrative records from nearly all 
general practices in the Auckland region. For ILI cases vaccination status was taken from 
the general practice record. In New Zealand almost all influenza vaccinations are 
administered in general practices.
Laboratory Methods
Nasopharyngeal swabs, aspirates and other respiratory samples were collected according to 
hospital or general practice standard procedures. Samples were tested using the United 
States Centers for Disease Control and Prevention real time RT-PCR protocol [11] or the 
AusDiagnostic PCR protocol.[12]. RT-PCR assays detected influenza virus types A and B 
and subtyping was performed for type A. All influenza positive PCR cases were forwarded 
to the National Influenza Centre and a convenience sample were characterised antigenically 
using established methods [13].
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Univariate χ2-tests were undertaken to compare characteristics of patients who were 
influenza positive (cases) and negative (controls). A multivariate logistic model was used to 
calculate an odds ratio (OR) for the propensity to bet vaccinated for a range of patient 
characteristic used in previous studies [13]. The results from the propensity model are 
presented as odds ratios and were used to adjust the VE estimate.
For both SARI and ILI, we calculated the crude VE, adjusting only for the timing of the 
presentation relative to the influenza season (defined as week from the peak), and the 
adjusted VE, which included the timing of the presentation and a variable calculated from 
the cubic spline of the fitted values of the propensity model. The season was defined as the 
period with continuous weeks with at least two laboratory-confirmed influenza cases. It 
began on the week of 10th June 2013 and was continuing at 27th September 2013 when the 
analysis period ended.
For all patient characteristics, other than age and vaccination status, each missing data point 
was imputed simply as the baseline (referent) value for that data point. The baseline values 
used were: non-Māori, non-Pacific ethnicity, female, not low income, not pregnant, non-
smoker, without chronic disease, not obese, with self-rated health average or better, not on 
long term oxygen use and living without assistance. Sensitivity analyses were performed 
excluding individuals with missing data. VE estimates were calculated against both SARI 
and ILI, by influenza type and subtype and by age group (0–17, 18–64, 65+ years).
Results
A total of 886 SARI admissions and 1298 ILI patients were included in the analysis, of 
whom 182 (21%) and 391 (30%) were influenza positive, respectively. Of the 182 SARI 
admissions who tested inflenza positive, 67(38%) were vaccinated compared with 299/704 
(42%) who tested negative. Of the 391 ILI admissions who tested inflenza positive 37 (9%) 
were vaccinated compared with 170/979(17%) who tested negative (Table 1).
Influenza positive cases and influenza negative controls were compared across a range of 
patient characteristics. Patients less likely to test influenza positive for SARI and ILI were 
vaccinated, aged 6 months to 5 years or over 80 years, or those presenting outside the 
influenza season. In comparision to the community patients, the hospitalised patients were 
more likely to be vaccinated, to be older, to live in a deprived area, to be of Māori or Pacific 
ethnicity, to be a current smoker and to be obese (Table 1).
Of the 573 influenza cases detected in both SARI and ILI patients, 357 (62%) were type A 
(252 H3N2, 40 H1N1 and 65 not subtyped) and 221 (39%) type B (55 B/Wisconsin/1/2010-
like of the B/Yamagata lineage, 4 B/Brisbane/60/2008-like of the B/Victoria lineage and 162 
where the B lineage was not determined) (Table 2). Five cases tested positive for both 
influenza A and B.
Although vaccination was more common in SARI patients, the same factors affected the 
propensity to be vaccinated in persons with ILI or SARI. The adjusted odds ratios for the 
Turner et al. Page 4













association of various patient characteristics with the likelihood of vaccination showed that 
older age groups and those with chronic diseases were most likely to be vaccinated (Table 
3). In contrast, there was no statistically significant difference in the likelihood of 
vaccination by ethnicity, gender, income, pregnancy, obesity, self-rated health, smoking, 
assisted living or the timing of the admission relative to the influenza season (Table 3). 
Administrative GP records of vaccination were found for 215 (59%) and 33 (6%) SARI 
patients who reported being vaccinated and unvaccinated, respectively. Of the 151 SARI 
patients with unconfirmed self-reported vaccination, 112 (74%) reported they were 
vaccinated at their genearl practice.
Vaccine Effectiveness
The VE against all circulating strains, adjusted only for week from the peak of the season, 
was 28% (95% confidence interval (CI): −5;47) for influenza-confirmed SARI and 53% 
(95% CI: 29;68) for influenza-confirmed ILI (Table 4). After also adjusting for the 
propensity to be vaccinated, the estimated VE was 52% (95% CI: 27;68) for SARI and 53% 
(95% CI: 28;70) for ILI. Adjusting for the propensity to be vaccinated had more effect on 
the VE estimate for SARI than adjusting for week of onset. For ILI the VE crude and 
adjusted point estimates were the same. There was no significant change to these estimates 
when excluding patients with missing values (data not shown) or when a logistic regression 
model was constructed and directly adjusted for all the covariates in table 2. For example, 
for SARI patients the VE was 56% (95% CI: 28;73) using this model. Adjusting for only the 
variables that were significant in the model (p<0.05) resulted in a VE estimate of 55% (95% 
CI: 27,52).
The vaccine was significantly protective among patients aged 18–64 years. Specifically VE 
was 60% (95% CI: 26;78) against influenza-confirmed SARI and 60% (95% CI: 29;77) 
against influenza-confirmed ILI. In the 1,005 patients in this age group, 7 were pregnant and 
241 had co-morbidities. VE point estimates for those aged 0–17 and 65+ years were similar 
(45% and 40%, respectively), although confidence intervals included zero (Table 4).
For ILI patients, VE against influenza A was 55% (95% CI: 24;74) and against influenza B 
was 53% (95% CI: 13;75). For SARI patients VE against influenza A was 42% (95% CI: 
6;64) and against influenza B was 70% (95% CI: 40;84) (Table 4).
Most of the 40 A(H1N1) viruses characterized were closely related to A/California/7/2009 
virus. Almost all of the 252 influenza A(H3N2) viruses characterized were similar to A/
Victoria/361/2011-like virus. B/Yamagata lineage viruses were the predominant B viruses in 
New Zealand in 2013. Although this lineage was included in the 2013 Southern Hemisphere 
vaccine formulation, antigenic drift was observed in these viruses as they reacted better with 
ferret sera raised against B/Massachusetts/2/2012-like virus (selected for the Southern 
Hemisphere 2014 vaccine) than B/Wisconsin/1/2010 virus (included in the Southern 
Hemisphere 2013 vaccine).
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The 2013 NZ influenza season was characterised by low incidence and a late peak, with 
virus circulation continuing at the time of this analysis. Influenza A(H3N2) and influenza B 
predominated. The circulating influenza A sub-types were antigenically similar to the H1 
and H3 components of the 2013 vaccine, while the predominant circulating B viruses were 
lineage matched, although antigenic drift was observed.
This is the first study comparing VE against medically attended ILI and hospitalised SARI 
due to laboratory confirmed influenza in in the same season in New Zealand. We have 
demonstrated moderate VE, around 50%, against both outcomes. There was unlikely to be a 
substantial difference in VE by severity of influenza illness, represented by ILI or SARI, 
although the study was not powered to test for this. Our estimates were made before the 
season had finished but they are late season estimates and are likely to be predictive of the 
final VE [14].
VE estimates were similar for all types and sub-types, with a tendency towards lower VE for 
H1N1, but based on small numbers. Except for the 18 to 64 year age group, where the 
vaccine prevented about 60% of both ILI presentations and SARI hospitalisations, the 
sample size was too small to make definitive VE estimates by age group. Our point estimate 
for VE against medically attended influenza-confirmed ILI was very similar to northern 
hemisphere estimates for the 2012/13 influenza season, with interim adjusted estimates of 
56% from the US [15], a UK mid-season estimate of 51% (95% CI: 27;68) [16] and a 
Canadian interim estimate of 45% (95% CI: 13;66) [17].
While we collected information on most known potential confounding variables, we could 
not control for residual confounders. In future years we will collect data on previous 
presentations with respiratory illnesses and previous vaccination. New Zealand intends to 
add influenza vaccination to the national immunisation register in 2014. This will provide 
more accurate vaccination history than patient reported status for SARI patients.
In conclusion this study shows a moderate protective effectiveness of influenza vaccine 
against medically-attended and hospitalised influenza, supporting the current national 
immunisation strategy in New Zealand. The similarity of the VE estimates, obtained in the 
same population and at the same time, suggests that influenza vaccine has similar protective 
benefit against more severe hospitalised disease as against illness of mild to moderate 
severity. Pooled data from future SHIVERS years will allow more precise VE estimates for 
high risk subgroups and will also allow more extensive comparisons between VE estimates 
in primary care (general practice) and hospital settings.
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Table 1
Influenza-like illness and Severe Acute Respiratory Illness patient characteristics
Hospitalised with Severe
Acute Respiratory Illness










Vaccinated n (%) 67(36.8%) 299(42.5%) 37 (9.5%) 170(17.4%)
Median Age (years) 49 40 27 23
Age Group 0 to 5 years 36(19.8%) 239(34%) 55(14.2%) 235(24.0%)
6 to 17years 10(5.5%) 27(3.8%) 116(29.7%) 209(21.4%)
18 to 45 years 39(21.4%) 116(16.5%) 146(37.3%) 333(34.0%)
46 to 64 years 41(22.5%) 129(18.3%) 58(14.8%) 153(15.6%)
65 to 79 years 42(23.1%) 120(17.1%) 14(3.6%) 43(4.4%)
80+years 14(7.7%) 73(10.4%) 2(0.5%) 6(0.6%)
Male 83(45.6%) 353(50.1%) 175(44.8%) 399(40.8%)
Maori 25(13.7%) 143(20.3%) 13(3.3%) 53(5.4%)
Pacific 62(34.1%) 206(29.3%) 82(21%) 201(20.5%)
Mean NZDep score (by decile)1 7 7.1 5 5
Pregnant 4(2.2%) 3(0.4%) Not collected Not collected
Smoker 21(11.5%) 76(10.8%) 23(5.9%) 58(5.9%)
Chronic Disease 110(60.4%) 435(61.8%) Not collected Not collected
Obese 30(16.5%) 103(14.6%) 17(4.4%) 42(4.3%)
SF36- (poor or fair)2 23(12.6%) 115(16.3%) Not collected Not collected
Long Term Oxygen use 4(2.2%) 19(2.7%) Not collected Not collected
Dependence 8(4.4%) 41(5.8%) Not collected Not collected
Pre-Season 8(4.4%) 184(26.1%) 25(6.4%) 374(38.2%)
1
A meshblock measure reflecting eight dimensions of deprivation distributed into deciles
2
A self-defined, standardised functional well-being health status score
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Table 2




Hospitalised with Severe Acute
Respiratory Illness (SARI)
General Practice visit for influenza-like
illness (ILI)
Vaccinated (%) Unvaccinated (%) Vaccinated (%) Unvaccinated (%)
All 67 115 37 354
A(H1N1) 6 (9%) 6 (5.2%) 3 (8.1%) 25 (7.1%)
A(H3N2) 37 (55.2%) 49 (42.6%) 15 (40.5%) 151(42.7%)
All A 53 (79.1%) 71(61.7%) 23 (62.2%) 210 (59.3%)
All B 14 (20.9%) 45 (39.1%) 14 (37.8%) 148 (41.8%)
*
SARI case and 4 ILI cases tested positive for both influenza A and B. Not all cases of influenza A were sub-typed. Sub-types do not add to all 
influenza A.
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Table 3
Severe Acute Respiratory Illness and Influenza-like Illness patient characteristics and their association with 
influenza vaccination status*
Hospitalised with Severe Acute
Respiratory Illness







Age 6 months to 5 yrs 0.05 (0.02–0.1) <0.01 0.1(0.05 – 0.19) <0.01
Age 6 to 17 yrs 0.07 (0.02 – 0.24) <0.01 0.21 (0.13 – 0.34) <0.01
Age 18 to 45 yrs 0.32 (0.19 – 0.52) <0.01 0.3 (0.2 – 0.46) <0.01
Age 65 to 79 yrs 2.6 (1.54 – 4.37) <0.01 5.1 (2.66 – 9.79) <0.01
Age 80 + yrs 2.36 (1.23 – 4.53) 0.01 12.43(1.48 – 104.34) 0.02
Maori 0.62 (0.36 – 1.04) 0.07 0.93 (0.43 – 2.01) 0.85
Pacific 1.05 (0.65 – 1.7) 0.85 0.69 (0.41 – 1.18) 0.18
Male 0.97 (0.82 – 1.13) 0.67 0.71 (0.5 – 1.01) 0.06
NZDep score 1.03 (0.96 – 1.11) 0.36 0.97 (0.91 – 1.04) 0.44
Pregnant 1.18 (0.21 – 6.72) 0.85 Not collected
Smoker 1.03 (0.61 – 1.71) 0.92 0.61 (0.31 – 1.21) 0.16
Chronic disease 1.74 (1.08 – 2.82) 0.02 Not collected
Obese 1.05 (0.65 – 1.72) 0.83 1.48 (0.72 – 3.05) 0.29
Sf36- 1.11 (0.67 – 1.84) 0.69 Not collected
Frailty 3.32 (0.91 – 12.07) 0.07 Not collected
Dependence 1.58 (0.67 – 3.73) 0.29 Not collected
Early Season 0.72 (0.41 – 1.29) 0.27 1.06 (0.62 – 1.82) 0.83
Weeks from influenza peak 0.98 (0.92 – 1.03) 0.37 0.98 (0.93 – 1.03) 0.39
*
Adjusted odds ratio compared to referent group: female, aged 46 to 64 years, non-Māori non-Pacific ethnicity, not low income, not pregnant, non-
smoker, without chronic disease, not obese, with self-rated health average or better, not on long term oxygen use, living without assistance and 
admitted to hospital for SARI during the influenza season.


















































































































































































































































































































































































































































































































































































Euro Surveill. Author manuscript; available in PMC 2015 October 30.
